Ginkgo Bioworks Launches ADME-One Platform for Drug Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 51 minutes ago
0mins
Source: Newsfilter
- Product Innovation: Ginkgo Bioworks, in collaboration with Tangible Scientific and Inductive Bio, has launched the ADME-One platform, which offers a high-throughput Tier 1 ADME panel combined with AI-driven human pharmacokinetic projections, significantly enhancing the efficiency and quality of drug discovery decisions.
- Cost Reduction: The introduction of ADME-One not only lowers the cost of an ADME panel but also transforms the timing of data utilization in the drug discovery process, enabling scientists to conduct comprehensive series characterization at earlier stages, thereby reducing surprises and synthesis waste later on.
- Integrated Workflow: The platform unites the best capabilities of three companies, providing standardized workflows that ensure data generation reliability and consistency, which accelerates the prioritization and validation of drug candidates.
- Market Response: In the context of U.S. and European drug developers responding to the BIOSECURE Act, ADME-One delivers a fully U.S.-based workflow that meets the growing demand for data sovereignty, which is expected to drive the company's market share in the biopharma industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.410
Low
12.00
Averages
12.00
High
12.00
Current: 8.410
Low
12.00
Averages
12.00
High
12.00
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ginkgo Bioworks Launches ADME-One Platform for Drug Discovery
- Product Innovation: Ginkgo Bioworks, in collaboration with Tangible Scientific and Inductive Bio, has launched the ADME-One platform, which offers a high-throughput Tier 1 ADME panel combined with AI-driven human pharmacokinetic projections, significantly enhancing the efficiency and quality of drug discovery decisions.
- Cost Reduction: The introduction of ADME-One not only lowers the cost of an ADME panel but also transforms the timing of data utilization in the drug discovery process, enabling scientists to conduct comprehensive series characterization at earlier stages, thereby reducing surprises and synthesis waste later on.
- Integrated Workflow: The platform unites the best capabilities of three companies, providing standardized workflows that ensure data generation reliability and consistency, which accelerates the prioritization and validation of drug candidates.
- Market Response: In the context of U.S. and European drug developers responding to the BIOSECURE Act, ADME-One delivers a fully U.S.-based workflow that meets the growing demand for data sovereignty, which is expected to drive the company's market share in the biopharma industry.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Ginkgo Bioworks Outlines FY26 Cash Burn Guidance Amid Stock Plunge
- Cash Burn Guidance: Ginkgo Bioworks projected a cash burn of $125M to $150M for FY26 during its Q1 earnings report, leading to a nearly 14% drop in stock price to $8.97 on Friday, indicating market concerns about its financial stability.
- Quarterly Performance: The company reported an EPS of -$1.28, slightly better than analysts' expectations, but revenue fell 50% year-over-year to $19M, primarily due to ongoing program rationalization and restructuring efforts, highlighting the challenges faced by the firm.
- Reduced Cash Burn: Cash burn for the first quarter was $48M, down 17% from $58M in the same quarter last year, which included a $14M payment to Google Cloud, reflecting the initial effectiveness of restructuring measures.
- Stock Price Fluctuations: Despite gaining 3.81% and 2.38% on Wednesday and Thursday respectively, Friday's decline erased previous gains, although the stock is up 7.22% year-to-date, moving in line with broader market trends.
See More
Ginkgo Bioworks Q1 2026 Earnings Call Insights
- Significant Revenue Decline: Ginkgo reported $19 million in revenue for Q1 2026, a 49% year-over-year decrease primarily due to $7.5 million in non-cash revenue from Q1 2025, indicating substantial challenges in revenue growth.
- Cash Burn Management: The company reaffirmed its cash burn guidance for 2026 at $125 million to $150 million, emphasizing a balance between cost efficiency and ongoing services, reflecting management's cautious approach to future investments.
- Biosecurity Spin-off: Ginkgo successfully completed the spin-off of its biosecurity unit, raising $60 million and becoming a shareholder in the new company Perimeter, allowing the company to focus on strategic development in autonomous labs.
- Nebula Expansion Progress: The Nebula lab is set to bring online 103 racks imminently, with CEO noting over 50 racks currently operational and 439 scientists submitting experiments on peak days, showcasing positive advancements in technology scaling and user engagement.
See More
Ginkgo Bioworks to Host Q1 Performance Review on May 7, 2026
- Earnings Presentation Scheduled: Ginkgo Bioworks plans to host a performance review on May 7, 2026, at 4:30 p.m. ET, focusing on Q1 results ending March 31, 2026, aimed at providing transparency and future outlook to investors.
- Interactive Q&A Session: Investors can submit questions via social media platform X (Twitter) using the hashtag #GinkgoResults or through email ahead of the presentation, enhancing interaction with management and increasing investor engagement.
- Investor Relations Website: Details and a webcast link for the presentation will be available on Ginkgo's investor relations website, ensuring all investors can easily access relevant information and participate in the replay, thereby improving information accessibility.
- Company Background: Ginkgo Bioworks focuses on developing tools for biological engineering, offering automated laboratory services that aim to enhance scientists' productivity through robotics, driving innovation and growth in the biotechnology sector.
See More
Ginkgo Bioworks Launches ADME-One Platform for Drug Discovery
- Product Innovation: Ginkgo Bioworks, in collaboration with Tangible Scientific and Inductive Bio, has launched the ADME-One platform, which offers a high-throughput Tier 1 ADME panel combined with AI-driven human pharmacokinetic projections, significantly enhancing the efficiency and quality of drug discovery decisions.
- Cost Reduction: The introduction of ADME-One not only lowers the cost of an ADME panel but also transforms the timing of data utilization in the drug discovery process, enabling scientists to conduct comprehensive series characterization at earlier stages, thereby reducing surprises and synthesis waste later on.
- Integrated Workflow: The platform unites the best capabilities of three companies, providing standardized workflows that ensure data generation reliability and consistency, which accelerates the prioritization and validation of drug candidates.
- Market Response: In the context of U.S. and European drug developers responding to the BIOSECURE Act, ADME-One delivers a fully U.S.-based workflow that meets the growing demand for data sovereignty, which is expected to drive the company's market share in the biopharma industry.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Ginkgo Bioworks Outlines FY26 Cash Burn Guidance Amid Stock Plunge
- Cash Burn Guidance: Ginkgo Bioworks projected a cash burn of $125M to $150M for FY26 during its Q1 earnings report, leading to a nearly 14% drop in stock price to $8.97 on Friday, indicating market concerns about its financial stability.
- Quarterly Performance: The company reported an EPS of -$1.28, slightly better than analysts' expectations, but revenue fell 50% year-over-year to $19M, primarily due to ongoing program rationalization and restructuring efforts, highlighting the challenges faced by the firm.
- Reduced Cash Burn: Cash burn for the first quarter was $48M, down 17% from $58M in the same quarter last year, which included a $14M payment to Google Cloud, reflecting the initial effectiveness of restructuring measures.
- Stock Price Fluctuations: Despite gaining 3.81% and 2.38% on Wednesday and Thursday respectively, Friday's decline erased previous gains, although the stock is up 7.22% year-to-date, moving in line with broader market trends.
See More
Ginkgo Bioworks Q1 2026 Earnings Call Insights
- Significant Revenue Decline: Ginkgo reported $19 million in revenue for Q1 2026, a 49% year-over-year decrease primarily due to $7.5 million in non-cash revenue from Q1 2025, indicating substantial challenges in revenue growth.
- Cash Burn Management: The company reaffirmed its cash burn guidance for 2026 at $125 million to $150 million, emphasizing a balance between cost efficiency and ongoing services, reflecting management's cautious approach to future investments.
- Biosecurity Spin-off: Ginkgo successfully completed the spin-off of its biosecurity unit, raising $60 million and becoming a shareholder in the new company Perimeter, allowing the company to focus on strategic development in autonomous labs.
- Nebula Expansion Progress: The Nebula lab is set to bring online 103 racks imminently, with CEO noting over 50 racks currently operational and 439 scientists submitting experiments on peak days, showcasing positive advancements in technology scaling and user engagement.
See More
Ginkgo Bioworks to Host Q1 Performance Review on May 7, 2026
- Earnings Presentation Scheduled: Ginkgo Bioworks plans to host a performance review on May 7, 2026, at 4:30 p.m. ET, focusing on Q1 results ending March 31, 2026, aimed at providing transparency and future outlook to investors.
- Interactive Q&A Session: Investors can submit questions via social media platform X (Twitter) using the hashtag #GinkgoResults or through email ahead of the presentation, enhancing interaction with management and increasing investor engagement.
- Investor Relations Website: Details and a webcast link for the presentation will be available on Ginkgo's investor relations website, ensuring all investors can easily access relevant information and participate in the replay, thereby improving information accessibility.
- Company Background: Ginkgo Bioworks focuses on developing tools for biological engineering, offering automated laboratory services that aim to enhance scientists' productivity through robotics, driving innovation and growth in the biotechnology sector.
See More
